Ilya Rachman
Chief Executive Officer en IMMIX BIOPHARMA, INC. .
Fortuna: 3 M $ al 31/03/2024
Perfil
Ilya Rachman is a Chairman & Chief Executive Officer and founder of Immix Biopharma, Inc. which is founded in 2012.
He is also currently an Executive Chairman at Nexcella, Inc. Dr. Rachman has an MBA from the University of California, Los Angeles, a graduate and doctorate degree from the University of Illinois, and an undergraduate degree from the University of Iowa.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
IMMIX BIOPHARMA, INC.
3.53% | 14/08/2023 | 902 500 ( 3.53% ) | 3 M $ | 31/03/2024 |
Cargos activos de Ilya Rachman
| Empresas | Cargo | Inicio |
|---|---|---|
| IMMIX BIOPHARMA, INC. | Chief Executive Officer | 01/01/2012 |
Nexcella, Inc.
 Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The private company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Chairman | - |
Formación de Ilya Rachman.
| University of California, Los Angeles | Masters Business Admin |
| University of Illinois | Doctorate Degree |
| University of Iowa | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| IMMIX BIOPHARMA, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The private company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Health Technology |
- Bolsa de valores
- Insiders
- Ilya Rachman
